Debt-free Balance SheetZero reported debt materially reduces refinancing and interest-rate risk, preserving financial flexibility. For a capital-intensive biotech scaling fermentation production, a debt-free balance sheet lengthens runway, eases partnership or equity funding negotiations, and supports project continuity over months.

Scalable Fermentation ManufacturingOwnership of fermentation-based manufacturing and downstream processing is a durable operational capability. It underpins potential cost reductions and scale efficiencies for PHA and bacterial cellulose, enabling the company to convert R&D into repeatable commercial production if yields and scale-up execution improve.

Position In Sustainable Materials MarketExposure to PHA bioplastics and bacterial cellulose aligns the company with long-term structural demand for sustainable materials. These secular trends expand the addressable market over years, offering lasting market tailwinds if the firm can commercialize cost-competitive, scalable bio-based products.

Bears Say

Structural UnprofitabilityNegative gross margins and persistently deep operating/net losses across reported years indicate structural unprofitability. Without demonstrable gross-profit recovery or a clear path to scale revenue, losses will likely continue, eroding capital and constraining reinvestment capacity over the medium term.

Chronic Negative Cash FlowConsistent negative operating and free cash flow, with accelerating cash burn in 2025, signals the business is not self-funding. This raises the probability of external financing needs, shareholder dilution, or dependence on partners, increasing execution and liquidity risk over the next several quarters.

Small, Declining And Volatile RevenueVery small, volatile revenue that declined in 2024–2025 undermines operating leverage and the ability to absorb fixed costs. Lack of stable top-line growth delays margin expansion, weakens negotiating power with suppliers/customers, and heightens the need for recurring funding or restructuring to reach scale.

Bioextrax AB News

Is 85X0 a Buy, Before Earnings?

Bioextrax AB (85X0) is scheduled to report 4th quarter earnings on 02/19/2026. Regarding Q4 estimates, Wall Street analysts...

7d ago

85X0 FAQ

What was Bioextrax AB’s price range in the past 12 months?

Bioextrax AB lowest stock price was €0.15 and its highest was €0.34 in the past 12 months.

What is Bioextrax AB’s market cap?

Bioextrax AB’s market cap is €13.05M.

When is Bioextrax AB’s upcoming earnings report date?

Bioextrax AB’s upcoming earnings report date is May 14, 2026 which is in 80 days.

How were Bioextrax AB’s earnings last quarter?

Bioextrax AB released its earnings results on Feb 19, 2026. The company reported €0 earnings per share for the quarter, the consensus estimate of €0 by €0.

Is Bioextrax AB overvalued?

According to Wall Street analysts Bioextrax AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioextrax AB pay dividends?

Bioextrax AB does not currently pay dividends.

What is Bioextrax AB’s EPS estimate?

Bioextrax AB’s EPS estimate is 0.

How many shares outstanding does Bioextrax AB have?

Bioextrax AB has 46,306,927 shares outstanding.

What happened to Bioextrax AB’s price movement after its last earnings report?

Bioextrax AB reported an EPS of €0 in its last earnings report, expectations of €0. Following the earnings report the stock price went up 2.92%.

Which hedge fund is a major shareholder of Bioextrax AB?

Currently, no hedge funds are holding shares in DE:85X0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bioextrax AB

Bioextrax AB (publ) develops and commercializes a bio-based extraction platform technology. It harvests bioplastics (PHA) granules, organic hydrolyzed protein, keratin fibers, bio-oils, protein-rich by products, and amino acids from bacteria. The company was incorporated in 2014 and is based in Lund, Sweden.